Clinical Efficacy and safety of Arogyavardhini Vati and Pippalyadyasava in the management of Non-Alcoholic Fatty Liver Disease (NAFLD) â??An open level prospective clinical trial

CCRAS0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年2月21日

研究概览

暂无简介。

•Diagnosed cases of Grade- I&II of Non-alcoholic fatty liver disease as evident fatty infiltration on Ultrasound.
•Either sex aged between18- 60 years.
•Subjects of non-alcoholic fatty liver disease with their hepatic enzymes <2 times upper normal limit (Normal limits AST 5-40U/L and ALT 7-56U/L).
•Willing to provide written consent and able to participate for 4 months in the study.

•H/o habitual consumption of alcohol intake of >20g/day for women, >40g/day for men
•Any other identified cause of chronic liver disease
•The use of medication which would cause non-alcoholic fatty liver - disease e.g. tamoxifen
•Already taking supplementary medicine for NAFLD
•On anticoagulants (antiplatelet aggregators are permitted)
•Past history of Cardiac Arrhythmia, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
•Symptomatic patients with clinical evidence of congestive cardiac failure.
•Subjects with concurrent Renal Dysfunction (defined as S. creatinine > 1.2 mg/dl), uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or other concurrent severe disease.
•Uncontrolled Diabetes Mellitus (HbA1C >8)
•Known cases of HIV and AIDS, malignancy, Hepatitis B
•Subjects participated in any other clinical trial.
•Women who are planning for conception / pregnant or lactating.Any other condition which the P.I. thinks may jeopardize the study.

发起方

CCRAS